Alphatec Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Spine surgery market penetration remains low, but rapid growth is driven by clinical innovation, procedural adoption, and technology integration. International expansion and operational leverage have led to positive EBITDA, improved cash flow, and strong financial guidance for 2026.
-
Q1 2026 revenue grew 14% year-over-year to $192 million, with surgical revenue up 17% and strong procedural and surgeon adoption. EOS revenue lagged due to installation delays, but guidance for 2026 remains robust, with 15% revenue growth and 17% surgical growth expected.
-
Strong growth and profitability were achieved through clinical distinction, surgeon adoption, and share gains amid industry disruption. Enabling technologies like the Valence robot support procedural integration, while disciplined capital deployment and efficient sales force expansion underpin continued confidence in future growth.
-
Consistent execution and innovation have driven strong growth, with 2025 revenue at $764 million and a target of $890 million for 2026. Investments in informatics and procedural integration, along with international expansion and robust profitability, position the company for continued success.
Fiscal Year 2025
-
Q4 and full-year 2025 saw 20% and 25% revenue growth, respectively, with strong margin expansion and positive free cash flow. 2026 guidance was raised for both revenue and Adjusted EBITDA, driven by innovation, surgeon adoption, and operational leverage.
-
Lateral spine procedures and robotics are driving strong growth, with significant market expansion potential through technology integration and sales force development. Informatics and automation are set to further differentiate offerings, while disciplined investment supports self-funded growth.
-
Q3 revenue grew 30% year-over-year to $197 million, with adjusted EBITDA at $26 million and strong free cash flow. Full-year guidance was raised to $760 million, driven by robust adoption in surgical and EOS segments, and the company remains on track for its 2027 financial targets.
-
Sustained revenue growth and profitability are driving positive cash flow, with 21% top-line growth expected in 2024 and continued investments in innovation, notably the Valence robot launch. International expansion remains focused, and the lateral portfolio is the main growth driver.
-
Q2 2025 delivered 27% revenue growth and record adjusted EBITDA, with strong same-store sales and surgeon adoption. Full-year guidance was raised for both revenue and EBITDA, and positive free cash flow is expected to continue.
-
Q1 2025 delivered 22% revenue growth and record surgical adoption, with adjusted EBITDA up over 800 bps year-over-year. Guidance for 2025 was raised, with strong cash flow and margin expansion expected, while new product launches and international growth continue to drive momentum.
-
A recent $405 million refinancing extended debt maturities to 2030, supporting strong 20% revenue growth projections for 2025, driven by lateral franchise expansion, new product launches, and international growth. Margin expansion and positive cash flow are expected, with operational leverage and a growing sales force supporting future performance.
-
A turnaround strategy focused on procedural innovation and informatics has driven rapid, profitable growth and market share gains. Integration of advanced imaging, AI-driven planning, and real-time neurologic monitoring supports clinical distinction and expansion. International growth and new technology launches are expected to further boost performance.
Fiscal Year 2024
-
Q4 2024 saw 28% revenue growth and strong profitability, with full-year revenue up 27% to $612 million and Adjusted EBITDA of $31 million. 2025 guidance projects 20% revenue growth, $75 million Adjusted EBITDA, and positive cash flow, driven by continued innovation and market expansion.
-
Strong market growth, robust financial improvement, and innovative technology position the business for continued share gains. Strategic investments in inventory, sales force, and product development support a long-term growth trajectory, with break-even cash flow targeted for 2025.
-
Sequential growth is driven by competitive sales hires and strong lateral procedure adoption, with technological differentiation in neuromonitoring and imaging. EOS platform rollout is in early stages, with broader impact expected from 2027. Profitability and cash flow are on track, supported by prudent spending and completed investments.
-
Q3 revenue grew 27% year-over-year to $151 million, with strong surgical and EOS segment performance, record surgeon training, and positive adjusted EBITDA. 2024 guidance was raised, cash burn reduced, and liquidity enhanced by a $50 million term loan expansion.
-
Management expects a significant reduction in inventory investment and a path to free cash flow break even in 2025, with no further capital raise planned. Revenue growth is driven by strong surgeon adoption, robust sales force expansion, and new technology launches, including a robotic platform and EOS Insight. International growth will focus on direct operations in select markets.
-
Q2 revenue grew 25% year-over-year to $145.6M, with strong surgical and EOS segment performance. Adjusted EBITDA turned positive, and the EOS Insight platform launched on time, driving record surgeon adoption. Full-year guidance was raised, with free cash flow breakeven expected in 2025.
-
Strong procedural innovation and targeted market strategies have driven rapid growth and margin expansion, with continued investment in technology and selective international markets. Cash burn is front-loaded in 2024, with profitability and new product launches expected to support future growth.